BF
BFRI.US Biofrontera Inc
- Market cap
- USD 10.4M
- P/E
- -
- P/B
- 2.31x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BFRI.US undervalued?
Graham numberThe Graham number of Biofrontera Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biofrontera Inc fundamental analysis
No fundamental analysis for Biofrontera Inc yet.
Biofrontera Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Full company profileBiofrontera Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biofrontera Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 26.2M | 18.8M | 24.1M | 28.7M | 34.1M | 37.3M | 41.7M | 41.5M |
| Gross Profit | 13.8M | 9.78M | 11.4M | 13.5M | 16.6M | 18.7M | 32.8M | 32.8M |
| Operating Income | -14.9M | -9.61M | -25.2M | -18.6M | -22.7M | -17.2M | -9.15M | -15.1M |
| EBITDA | -8.15M | -7.46M | -36.8M | 934K | -18.5M | -14.4M | -9.19M | -15.1M |
| Net Income | -11.0M | -11.0M | -37.7M | -640K | -20.1M | -17.8M | -10.5M | -15.7M |
| EPS | -18 | -19 | -44 | -0.61 | -13 | -3.22 | -0.90 | -1.03 |
| Balance Sheet | ||||||||
| Total Assets | 28.8M | 24.1M | 53.2M | 50.9M | 27.9M | 22.1M | 28.6M | 21.5M |
| Total Liabilities | 58.9M | 18.3M | 41.9M | 27.0M | 23.1M | 17.7M | 18.1M | 21.7M |
| Shareholders' Equity | -30.2M | 5.83M | 11.3M | 23.9M | 4.79M | 4.43M | 10.5M | -243K |
| Cash & Short-term Investments | 7.30M | 8.08M | 24.5M | 27.8M | 1.42M | 5.91M | 6.39M | 3.22M |
| Total Debt | 38.2M | - | - | 1.35M | 5.40M | 4.92M | 6.16M | 7.53M |
| Cash Flow | ||||||||
| Operating Cash Flow | -37.7M | -12.4M | -26.7M | -16.2M | -24.9M | -10.3M | -13.4M | -4.21M |
| Capital Expenditure | 538K | 11.0K | 11.0K | 38.0K | 5.00K | 60.0K | 2.00K | 18.7K |
| Free Cash Flow | -38.2M | -12.4M | -26.7M | -16.2M | -24.9M | -10.3M | -13.4M | -4.23M |
| Ratios | ||||||||
| ROE | - | -188.5% | -332.6% | -2.7% | -420.0% | -400.6% | -100.5% | - |
| ROA | -38.2% | -45.5% | -70.9% | -1.3% | -72.1% | -80.4% | -36.9% | -73.2% |
| Net Profit Margin | -41.9% | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% | -37.8% |
| Debt to Equity | - | - | - | 0.06x | 1.13x | 1.11x | 0.59x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biofrontera Inc dividends
Biofrontera Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Jul 5, 2023.
Who owns Biofrontera Inc
- Insiders 11.99%
- Institutions 31.04%
- Public & others 56.96%
- Shares outstanding 14.9M
- Free float 10.3M
Top funds holding BFRI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 66.2K | 0.45% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 7.49K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 422.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding BFRI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 1.28M | 8.59% | +9.59% | Jun 2026 |
| AIGH Capital Management, LLC | 740K | 4.98% | -19.15% | Jun 2026 |
| Renaissance Technologies Corp | 158K | 1.06% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 105K | 0.71% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 93.0K | 0.63% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 76.7K | 0.52% | -29.84% | Jun 2026 |
| Vanguard Capital Management, LLC | 71.4K | 0.48% | +36.60% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 61.7K | 0.42% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 51.9K | 0.35% | +130.71% | Jun 2026 |
| HRT FINANCIAL LLC | 43.3K | 0.29% | 0.00% | Jun 2026 |
| Northern Trust Corp | 31.5K | 0.21% | 0.00% | Jun 2026 |
| UBS Group AG | 18.5K | 0.12% | +1,102.47% | Jun 2026 |
| Sanctuary Advisors, LLC | 10.2K | 0.07% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 10.0K | 0.07% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 10.0K | 0.07% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.62K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 332.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 305.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
Biofrontera Inc company profile
- Company name
- Biofrontera Inc
- Ticker
- BFRI.US
- Exchange
- USA Stocks
- Listed since
- Oct 29, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 84
- Fiscal year end
- December
- Address
- 660 Main Street, Woburn, MA, United States, 01801
- Phone
- 781 245 1325
- Website
- biofrontera-us.com
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc management
7- Dr. Hermann Luebbert Ph.D.CEO, President & Chairman · born 1956
- Mr. Eugene Frederick Leffler IIIChief Financial Officer · born 1985
- Mr. George P. JonesChief Commercial Officer · born 1973
- Ms. Erica F. Gates CPA, M.B.A.VP of Finance & Principal Accounting Officer
- Mr. Jon Lyons M.B.A., Ph.D.Vice President of Scientific & Medical Affairs
- Mr. Daniel Hakansson J.D.Senior Corporate Counsel
- Ms. Samantha WiddicombeSenior Vice President of Sales & Strategic Accounts